← Back to Search

Prosthesis

Medacta GMK Sphere® vs. Medacta GMK PS for Osteoarthritis

N/A
Waitlist Available
Led By David Scott, MD
Research Sponsored by David F. Scott, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with intact collateral ligaments
Patients requiring a primary total knee replacement
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline at 2 years and 5 years post-operative
Awards & highlights

Study Summary

This trial is comparing two different types of knee replacements to see which is better.

Eligible Conditions
  • Arthritis
  • Osteoarthritis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your collateral ligaments are not injured or damaged.
Select...
You need to have a surgery to replace your entire knee joint.
Select...
You have been diagnosed with conditions like osteoarthritis, traumatic arthritis, or avascular necrosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline at 2 years and 5 years post-operative
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline at 2 years and 5 years post-operative for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Forgotten Joint Score (FJS)
Secondary outcome measures
Lower Extremity Activity Scale (LEAS)
Radiographic Analysis
Total Knee Society Score (KSS)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Medacta GMK Sphere® Medial-Pivot Knee ProsthesisExperimental Treatment1 Intervention
Group II: Medacta GMK PS Posterior Stabilized Knee ProsthesisExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

David F. Scott, MDLead Sponsor
1 Previous Clinical Trials
100 Total Patients Enrolled
Medacta USAIndustry Sponsor
16 Previous Clinical Trials
1,862 Total Patients Enrolled
1 Trials studying Arthritis
316 Patients Enrolled for Arthritis
David Scott, MDPrincipal InvestigatorSpokane Joint Replacement Center
3 Previous Clinical Trials
448 Total Patients Enrolled

Media Library

Medacta GMK PS Posterior Stabilized Knee Prosthesis (Prosthesis) Clinical Trial Eligibility Overview. Trial Name: NCT03391323 — N/A
Arthritis Research Study Groups: Medacta GMK Sphere® Medial-Pivot Knee Prosthesis, Medacta GMK PS Posterior Stabilized Knee Prosthesis
Arthritis Clinical Trial 2023: Medacta GMK PS Posterior Stabilized Knee Prosthesis Highlights & Side Effects. Trial Name: NCT03391323 — N/A
Medacta GMK PS Posterior Stabilized Knee Prosthesis (Prosthesis) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03391323 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it within my capacity to join this experiment?

"This joint disease trial will accept 218 patients who meet the following specifications: male and non-pregnant female between ages 21-80, with either osteoarthritis (OA), traumatic arthritis (TA) or avascular necrosis (AVN). Furthermore, participants must be willing to abide by postoperative weight bearing restrictions and self-evaluation protocols."

Answered by AI

Is this medical research open to participants of all ages, including those under 20?

"This trial has specified that the age range of participants should be between 21 and 80. There are 45 trials for minors, and 735 studies dedicated to individuals over 65 years old."

Answered by AI

Are any new participants currently being accepted into this clinical experiment?

"Per the data posted on clinicaltrials.gov, this research is not currently enrolling patients. Initially announced in April of 2015 and last updated on September 27th 2021, it has concluded its recruitment process; however, there are still 784 other trials actively seeking volunteers at the moment."

Answered by AI
~22 spots leftby Mar 2025